Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

Plain-language guide to NCT07707778: phase 4 non-randomized trial of Tirzepatide, 60 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07707778
Phase: phase 4
Status: enrolling by invitation
Start: 2026-06-25
Completion (planned or actual): 2027-12
Participants: 60 (estimated)
Design: non-randomized, open label (everyone knows who gets what), treatment
Conditions studied: Human Immunodeficiency Virus (HIV); Metabolic Dysfunction Associated Steatotic Liver Disease; Dyslipidaemia; Diabetes Mellitus; Obesity & Overweight; Metabolic Syndrome
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

The trial (phase 4) is built around Tirzepatide.

This study is a pilot, open-lable, two-arm study.

The investigators will enroll virally suppressed people living with HIV and obesity to evaluate the effect of tirzepatide on epigenetic aging, assessed by DNA methylation-based clocks using peripheral blood.

In parallel, imaging studies will be performed to assess changes in body composition and intrahepatic fat content.

It had two arms (groups): Interventional (experimental) and Standard of care (no intervention).

Participants enrolled in the standard of care arm will undergo identical imaging and blood testing, but without bictegravir PK/PD. They will receive diet and nutrition consult delivered via a smartphone-based application throughout the study course.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 60 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 0 inclusion and 1 exclusion criteria.

How the Study Was Run

Design: non-randomized, parallel-group and open-label.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

It started in 2026-06-25 with completion listed for 2027-12.

It ran at 1 site in Taiwan.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Second generation epigenetic aging clock (time frame: Baseline, week 33, week 57). Third generation epigenetic aging clock (time frame: Baseline, week 33, week 57).

It also tracked 20 secondary outcomes, for example Intrahepatic triglycerides, Change in body composition assessed by dual-energy X-ray absorptiometry (DXA), Change from baseline in body fat mass measured by bioelectrical impedance analysis (BIA), Patient reported outcome, Drinking habits and Body weight.

What This Means in Plain Language

Put simply, this is a phase 4, non-randomized trial of Tirzepatide in 60 people.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.

Our Notes on the Compound

Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.

Tirzepatide in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.